PHÂN TÍCH CHI PHÍ HIỆU QUẢ BẰNG MÔ HÌNH CỦA BUDESONIDE/FORMOTEROL KHI CẦN Ở NGƯỜI BỆNH HEN NHẸ TẠI VIỆT NAM

Abstract

Objectives: Cost-effectiveness analysis of Budesonide/Formoterol as needed compared with daily low dose inhaled corticosteroids (ICS) in combination with short-acting beta agonists as needed (SABA) in patients with mild asthma in Vietnam. Research methods: A probabilistic Markov cohort model was developed including three main states: non-exacerbation, severe exacerbation, and death. This study was carried out from the payer perspective, with a lifetime horizon and one-week cycle. Clinical parameters were derived from SYGMA 2 trial and costs were extracted from a cost-of-illness study in Vietnam and Drug Administration of Vietnam database. Results were expressed as an incremental cost-effectiveness ratio (ICER), results of one-way sensitivity analysis and probabilistic sensitivity analysis. Results: On average, as needed Budesonide/Formoterol was associated with VND 2,632,464 cost savings, quality-adjusted life year (QALY) gains of 0.0006 and 0.44 exacerbations avoided versus ICS combined with as-needed SABA. Budesonide/Formoterol thus dominated the comparator regarding cost-effectiveness. The results of one-way sensitivity analysis and probabilistic sensitivity analysis confirmed the robustness of the basecase results. Conclusion: From the payer perspective, Budesonide/Formoterol as needed saved cost while increasing effectiveness relative to the low-dose ICS combined with as-needed SABA regime in Vietnam.